Ignite Creation Date:
2024-05-05 @ 4:42 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00292487
Status:
COMPLETED
Last Update Posted:
2012-02-08
First Post:
2006-02-14
Brief Title:
Patients With Renal Impairment Undergoing CT
Sponsor:
Bracco Diagnostics Inc
Organization:
Bracco Diagnostics Inc
Study Overview
Official Title:
Isovue and Visipaque in Renally Impaired Patients Undergoing CT
Status:
COMPLETED
Status Verified Date:
2006-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to compare the incidence of contrast induced nephrotoxicity following the administration of Isovue or Visipaque in patients with mild to moderate renal impairment who undergo a clinically indicated IV contrast-enhanced multidetector computed tomography MDCT of the liver or MDCT angiography of the lower extremities Serum Creatinine SCr will be measured before and up to 48-72 hours post dose
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None